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Abstract In this study, we describe the activation of melano-
genesis by selective vacuolar type H+-ATPase inhibitors
(bafilomycin A1 and concanamycin A) in amelanotic human
and mouse melanoma cells which express tyrosinase but show no
melanogenesis. Addition of the inhibitors activated tyrosinase
within 4 h, and by 24 h the cells contained measurable amounts
of melanin. These effects were not inhibited by cycloheximide
(2 Wg/ml) which is consistent with a post-translational mechanism
of activation. Our findings suggest that melanosomal pH could
be an important and dynamic factor in the control of
melanogenesis in mammalian cells. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Melanin production by mammalian pigment cells is a pro-
cess involving a series of complex cellular events. Despite the
recent cloning and characterisation of several enzymes and
structural proteins (tyrosinase, tyrosinase-related proteins
type 1 and 2 (TRP-1 and -2), silver locus 100 kDa protein
(Gp100), melanoma-associated antigen recognised by T cells
(MART)) that are involved in the synthesis of melanin [1], our
understanding of this process and its regulation is still far
from clear. The copper containing metalloenzyme tyrosinase
(EC 1.14.18.1) which is speci¢c to melanocytes and catalyses
the initial steps in the melanogenesis pathway is considered to
be the rate limiting enzyme for melanin synthesis. Its absence,
as occurs in the hypopigmentary disorder tyrosinase negative
albinism, results in a complete absence of melanin.
As the key determinant for melanin synthesis, tyrosinase is
under a sophisticated control by transcriptional and transla-
tional mechanisms. Recently, there has been interest in the
role of post-translational events in the regulation of tyrosinase
activity [2^5]. It is recognised that variations in tyrosinase
activity in di¡erent pigment cells cannot be explained on the
basis of enzyme abundance [6]. For instance, amelanotic and
pigmented subclones of melanoma cells can have similar levels
of tyrosinase protein [7] and the same has been reported for
melanocytes from light Caucasian and black skin [8]. Further-
more, it has been shown that the stimulation of tyrosinase
activity and melanin synthesis occurs faster in cytoplasts
than in nucleated cells [9]. These results suggest that in
some pigment cells tyrosinase is present in a catalytically in-
active state and that its activation could be an important
control point for melanin synthesis.
Melanin production takes place within specialised intracel-
lular organelles known as melanosomes. Since catalytic do-
mains of tyrosinase are located on the inner side of the mel-
anosomal membrane, its activity could be dependent upon the
melanosomal environment. There is evidence that melano-
somes are closely related to lysosomes. For instance, both
organelles contain the same structural proteins (e.g. lyso-
some-associated membrane protein, acidic hydrolases, vacuo-
lar type proton pumps) [10,11] and both are a¡ected in genetic
disorders such as the Chediak^Higashi and Hermansky^Pu-
dlak syndromes [12,13]. More recently, it has been suggested
that the melanosome is accessible to endosomal transport and
represents a highly specialised lysosome rather than a com-
pletely unique structure [14,15]. This hypothesis is supported
by studies which have shown that when human diploid ¢bro-
blasts are transfected with tyrosinase and TRP-1, the enzymes
co-localise in lysosomes and melanogenesis occurs [16,17].
There are several reports that melanosomes are acidic or-
ganelles and when mature can have a pH as low as 4.0 [18,19].
It has been assumed that this low melanosomal pH facilitates
melanogenesis [20^22]. However, this is not consistent with
the ¢nding that mammalian tyrosinase has optimal enzymatic
activity at neutral pH [26^28] and shows little activity at
pH6 5. On the contrary, there are reports that agents which
raise lysosomal pH can increase tyrosinase activity. Thus in-
creases in tyrosinase activity have been reported in pigmented
mouse B16 melanoma cells in response to 10 mM NH4Cl and
the proton/metal ion exchanging ionophores, nigericin and
monensin [26,27]. This stimulatory activity occurred in intact
melanoma cells but not cell lysates, emphasising the impor-
tance of intact intracellular membranes. It was proposed that
an elevation of melanosomal pH could be responsible for the
increase in tyrosinase activity, although other possibilities
were not excluded. Ammonium chloride has been shown to
inhibit degradation of tyrosinase and increase its half-life by
3-fold [28], and ionophores could act by the facilitating ex-
change of univalent metal ions.
The purpose of this study was to investigate the e¡ect of
increasing melanosomal pH on melanogenesis. It has been
shown that the selective vacuolar type H-ATPase inhibitors
ba¢lomycin A1 (BafA1) and concanamycin A that target
acidic intracellular compartment pH [29,30] are e¡ective in
increasing pH in these compartments in melanocytic cells
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(N. Smit, personal communication). In the present study, we
examined the e¡ects of BafA1 and concanamycin A in ame-
lanotic but tyrosinase positive melanoma cells.
2. Materials and methods
2.1. Cells and cell cultures
Human melanoma cell lines FM3, FM57 and FM81 established
from metastatic melanoma nodules were gifts from Dr A.F. Kirkin.
The amelanotic mouse B16-G4F line was a gift from Prof. A. Eberle.
Melanoma cells were cultured in RPMI 1640 medium supplemented
with foetal bovine serum (10%). BafA1 and cycloheximide were ob-
tained from Sigma, geneticin (G418) from Gibco BRL and concana-
mycin A from Calbiochem.
2.2. Reverse transcription (RT)-PCR
Total RNA was isolated using TRI Reagent (Sigma). The quality of
RNA was tested by the A260/A280 ratio and 1.5% agarose gel electro-
phoresis. cDNA synthesis was performed with MoMLV reverse tran-
scription kit (Fermentas) following the manufacturer’s instruction us-
ing approximately 1 Wg of total RNA and 500 pmol of oligo(dT16)
primers in 20 Wl of reaction mixture. 1 Wl of cDNA was used for PCR
ampli¢cation in 50 Wl of reaction mixture containing: 1UPCR bu¡er
(50 mM KCl, 20 mM Tris pH 8.4), 2.5 mM MgCl2, 10 pmol of each
primer, 200 WM dNTP (Fermentas) and 1.0 U of recombinant Taq
polymerase (Fermentas). The parameters used for the ‘touch down’
ampli¢cation were initially 10 cycles of 94‡C for 30 s, 65‡C (decreas-
ing 0.5‡C per cycle) for 30 s and 72‡C for 1 min followed by 25 cycles
with the annealing temperature of 60‡C. Primers speci¢c for 284 bp
fragment of human and mouse tyrosinase were used (forward:
TTGGCAGATTGTCTGTAGCC; reverse: AGGCATTGTGCATG-
CTGCTT). The following primers were used to test human melanoma
lines only: 792 bp fragment of TRP-1 (forward: CACAAAGAG-
CTGCAAACC, reverse: AGGAAGGGAGAAAGAAGG); 873 bp
fragment of TRP-2 (forward: CCCTACATCCTACGAAACC, re-
verse: TTGAGAATCCAGAGTCCC); primers speci¢c for Gp100
and MART were used as described [31].
2.3. Tyrosinase activity
Tyrosinase activity was assayed by measuring the production of
radioactive water from tritiated L-tyrosine as described [26]. Brie£y,
L-[3,5-3H]tyrosine (46 Ci/mmol, from Amersham) was diluted in cell
culture medium to produce a ¢nal concentration of 5 WCi of L-[3,5-
3H]tyrosine per ml. Cells were returned to incubator and 200 Wl ali-
quots of medium were collected after periods of 4, 8 and 24 h. Protein
was precipitated by adding 200 Wl of 15% (w/v) trichloroacetic acid,
and the supernatant treated with 50 mg of Norit A charcoal slurry to
remove labeled tyrosine.
2.4. Melanin and protein assays
The amount of melanin was assayed by dissolving a washed cell
pellet directly in 1 ml of Soluene 350 (Packard Instruments) and in-
cubating the samples for 2 h at 60‡C. Synthetic melanin (Sigma) was
used to construct a standard curve for the range of 1^50 Wg of mel-
anin per ml of Soluene 350. Melanin absorbance was measured at
475 nm wavelength. Protein concentrations were determined with an
assay kit, based on the Lowry assay (Bio-Rad).
3. Results
3.1. Cell characterisation by RT-PCR
Both the B16-G4F and FM3 melanoma cells were found to
express tyrosinase mRNA. Although the FM57 and FM81
melanoma cells expressed melanocyte markers Gp100,
MART, TRP-1 and TRP-2, they showed no detectable ex-
pression of the tyrosinase gene (Fig. 1). The FM3 melanoma
cells also expressed Gp100, MART and TRP-2 but no TRP-1.
3.2. Tyrosinase activity and melanin
The levels of tyrosinase activity in FM3 and B16-G4F cells
were found to be almost undetectable under control condi-
tions. The FM57 and FM81 melanoma cells that were in-
cluded as controls contained no tyrosinase activity. No mela-
nin was detected in any of melanoma lines under control
conditions.
BafA1 and concanamycin A produced dose-related in-
creases in tyrosinase activity in the tyrosinase positive cell
lines FM3 and B16-G4F and as seen in Fig. 2, concanamycin
A was the more potent of the two compounds. This order of
potency correlates with their respective binding a⁄nities to
vacuolar type H-ATPase (Calbiochem general catalogue,
2000). Concentrations of both compounds in excess of
20 nM were cytotoxic (data not shown). Submaximal concen-
trations of 3 nM concanamycin A and 10 nM BafA1 were
therefore used in all subsequent experiments and as shown in
Fig. 2, these concentrations have similar potencies in stimulat-
ing tyrosinase activity. In response to 10 nM BafA1 and 3 nM
concanamycin A, cell lines showed a rapid and statistically
Fig. 1. RT-PCR for human and mouse tyrosinase mRNA. Human
melanocytes (positive control), lane 1; B16-G4F, lane 2; FM3, lane
3; FM57, lane 4; FM81, lane 5; 100 bp ‘ladder’ MW marker, lane
M.
Fig. 2. E¡ect of vacuolar type H-ATPase inhibitors on tyrosinase activity in FM3 (A) and B16-G4F (B) cells. The cells were incubated for
24 h with varying concentrations of concanamycin A (a) and BafA1 (b). Doses higher than 20 nM were toxic for cells.
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signi¢cant increase in tyrosinase activity which lasted for the
24 h duration of the experiment (Fig. 3). At this time, the cell
pellets were visibly darker and contained measurable amounts
of melanin (Fig. 4). The protein synthesis inhibitor cyclohex-
imide (2 Wg/ml) had no e¡ect on these increases in tyrosinase
activity (Fig. 5) and melanin (data not shown). Incubation of
the cells with a high dose of cycloheximide (10 Wg/ml) alone or
the cell cycle arresting agent geneticin (200 Wg/ml) failed to
induce tyrosinase activity and melanin production (data not
shown).
Incubation of the tyrosinase negative FM57 and FM81
melanoma cells with the same concentrations of BafA1 and
concanamycin A produced no detectable amounts of
[3H]water or melanin.
4. Discussion
A number of studies have suggested that tyrosinase in pig-
ment cells does not necessarily exist in a catalytically optimal
state [6,32]. There have also been several reports that activa-
tion of this enzyme can occur independently of increases in its
synthesis [5,33]. In the present study, the amelanotic, but ty-
rosinase positive, FM3 and B16-G4F melanoma cells were
found to contain almost undetectable levels of tyrosinase ac-
tivity and intracellular melanin was absent. However, in re-
sponse to BafA1 and concanamycin A, there was a rapid
increase in tyrosinase activity followed by melanin produc-
tion. The levels of melanin production and tyrosinase activity
in the FM3 and B16-G4F cells in response to BafA1 and
concanamycin A were comparable to those that we observe
in pigmented human melanocytes and B16-F1 mouse melano-
ma cells, respectively. A high dose of cycloheximide and a cell
cycle arresting concentration of geneticin had no e¡ect on
melanogenesis, eliminating the possibility that the increases
in melanogenesis were associated with non-speci¢c cytostatic
e¡ects of BafA1 and concanamycin A. The fact that the mel-
anogenesis response was not abolished by cycloheximide
makes it unlikely that tyrosinase abundance was increased
and points towards an activation of pre-existing enzyme. A
non-genomic mechanism is therefore implicated and this is
consistent with the rapid kinetics of tyrosinase activation.
Thus our ¢ndings support the view that under normal con-
ditions FM3 and B16-G4F melanoma cells contain tyrosinase
but because this is inactive, melanin synthesis is suppressed
and the cells exhibit an amelanotic phenotype. However, in
response to the vacuolar type proton pump inhibitors which
induce an increase in the pH of acidic intracellular compart-
ments, tyrosinase is activated and melanin production initi-
ated.
It has previously been reported that tyrosinase activity in
vitro is minimal at pH6 5 and that the enzyme is irreversibly
inactivated at a pH lower than 4 [23^25]. However, as the pH
rises, tyrosinase activity increases, reaching a maximal level at
near pH 7.0. This range of proton concentration (pH 5.0^7.0)
corresponds well with the variations of pH inside organelles of
the endosomal/lysosomal pathway that are created and main-
tained by proton pumps. As melanosomes are closely related
Fig. 3. Time course of tyrosinase activation by vacuolar type H-ATPase inhibitors in FM3 (A) and B16-G4F cells (B). The cells were incu-
bated for the indicated periods with: (R) complete medium (control); (a) 3 nM concanamycin A; (b) 10 nM BafA1.
Fig. 4. Melanin production in response to vacuolar type H-ATPase
inhibitors. Cells were collected after 24 h incubation in complete
medium (open bar) containing 3 nM concanamycin A (striped bar)
or 10 nM BafA1 (closed bar). The control values are below the level
of assay sensitivity (6 0.5 Wg/mg of protein).
Fig. 5. E¡ect of cycloheximide on tyrosinase activation by vacuolar
type H-ATPase inhibitors in FM3 cells. Cells were incubated for
24 h in complete medium (open bar) containing 3 nM concanamy-
cin A (striped bar) or 10 nM BafA1 (closed bar) with or without
cycloheximide (2 Wg/ml).
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to this group of acidic organelles, it is possible that they show
similar variations of pH and this could have physiological
importance for melanogenesis through a non-genomic control
of tyrosinase activity. It is of interest that cyclic AMP, which
has been reported to increase lysosomal pH [34], is a well-
recognised stimulator of melanogenesis. Melanogenesis also
occurs in response to ultraviolet (UV) irradiation and in-
creases have been observed in melanoma cells as early as 1^
3 h after UV irradiation [35]. The speed of this response
would suggest that non-genomic mechanism operates before
de novo synthesis of tyrosinase occurs. Whether this rapid
increase in melanin synthesis in response to UV is induced
by a change in melanosomal pH remains to be investigated.
Nevertheless, our results would suggest that melanosomal pH
could function as a ‘control switch’ providing pigment cells
with a fast and dynamic regulatory mechanism for melano-
genesis.
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